<4D F736F F D2095BD90AC E93785F8C C9F8DB8926C82A982E782DD82BD89C193FC8ED282CC8C928D4E8FF391D482C98AD682B782E992B28DB895AA90CD2E646F6378>
|
|
|
- あかり いそみ
- 5 years ago
- Views:
Transcription
1 29 7 IT , cm 2 100cm 2 BMI25kg/m 2 85cm90cm 85cm90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL HbA1c 5.6% 6.5% ASTGOT 31U/L 51U/L ALTGPT 31U/L 51U/L -GT-GTP 51U/L 101U/L 2 p.58 1 / 43
2 mmhg mg/dl mg/dl U/L LDL120 HDL HbA1c5.6% AST31 ALT31 -GT LDL120 HDL LDL LDL HbA1c5.6% 110 HbA1c6.0% 126 HbA1c6.5% AST31 ALT31 -GT51 AST51 ALT51 -GT101 2 HDL HbA1c 130mmHg 85mmHg 150mg/dL 40mg/dL 100mg/dL 5.6% 2 / 43
3 / 43
4 / 43
5 339 5, % 63.7% p.639.9% 17.1% , ,307 0% 20% 40% 60% 80% 100% / 43
6 0% 20% 40% 60% 80% 100% % 20% 40% 60% 80% 100% / 43
7 , , , , , ,351 1 HDL LDL HbA1cAST(GOT)ALT(GPT)γ-GT(-GTP) 7 / 43
8 115 6, %12.7%9.8% 2.4% 2.9% 2.2% 2.3% 1.7% 1.3% 3.5% 4.1% 30.2% 4.6% 5.4% 8.0% 12.7% 9.0% 9.8% 8 / 43
9 157 5, %13.7%7.4% 1.3% 1.7% 1.8% 1.2% 1.2% 4.4% 4.7% 1.1% 0.4% 0.4% 6.8% 46.4% 7.3% 7.4% 13.7% 9 / 43
10 % 16.1%16.9%12.9%4.0% p mmHg85mmHg 140mmHg90mmHg 130mmHg85mmHg 160mmHg100mmHg 67.0% 16.1% 12.9% 4.0% mmhg ,273, , , , % 3 1, , / 43
11 130mmHg85mmHg 140mmHg90mmHg 130mmHg85mmHg 160mmHg100mmHg 0% 20% 40% 60% 80% 100% mmHg85mmHg 140mmHg90mmHg 130mmHg85mmHg 160mmHg100mmHg 0% 20% 40% 60% 80% 100% / 43
12 4 38.4% 29.9%31.7%27.0%4.7% p LDL120mg/dLHDL40mg/dL150mg/dL LDL120mg/dLHDL40mg/dL150mg/dL LDL140mg/dL300mg/dL LDL180mg/dL1,000mg/dL 38.4% 29.9% 27.0% 4.7% mg/dl LDL120 HDL LDL120 HDL LDL LDL180 1,000 1,303, ,015, , , , , / 43
13 LDL120mg/dLHDL40mg/dL150mg/dL LDL120mg/dLHDL40mg/dL150mg/dL LDL140mg/dL300mg/dL LDL180mg/dL1,000mg/dL 0% 20% 40% 60% 80% 100% LDL120mg/dLHDL40mg/dL150mg/dL LDL120mg/dLHDL40mg/dL150mg/dL LDL140mg/dL300mg/dL LDL180mg/dL1,000mg/dL 0% 20% 40% 60% 80% 100% / 43
14 5 69.4% %7.14.9% p mg/dL)HbA1c5.6% 100mg/dLHbA1c5.6% 110mg/dLHbA1c6.0% 126mg/dLHbA1c6.5% 69.4% 18.5% 7.1% 4.9% mg/dl 100 )HbA1c5.6% 100 )HbA1c5.6% 110 )HbA1c6.0% 126 )HbA1c6.5% 2,350, , , , , , / 43
15 100mg/dL)HbA1c5.6% 100mg/dLHbA1c5.6% 110mg/dLHbA1c6.0% 126mg/dLHbA1c6.5% 0% 20% 40% 60% 80% 100% mg/dL)HbA1c5.6% 100mg/dLHbA1c5.6% 110mg/dLHbA1c6.0% 126mg/dLHbA1c6.5% 0% 20% 40% 60% 80% 100% / 43
16 6 69.1% 20.4%10.5% p AST<31U/LALT<31U/Lγ-GT<51U/L AST31U/LALT31U/Lγ-GT51U/L AST51U/LALT51U/Lγ-GT101U/L 69.1% 20.4% 10.5% U/L AST31 ALT31 -GT51 AST31 ALT31 -GT51 AST51 ALT51 -GT101 2,346, , , , , / 43
17 AST<31U/LALT<31U/Lγ-GT<51U/L AST31U/LALT31U/Lγ-GT51U/L AST51U/LALT51U/Lγ-GT101U/L 0% 20% 40% 60% 80% 100% AST<31U/LALT<31U/Lγ-GT<51U/L AST31U/LALT31U/Lγ-GT51U/L AST51U/LALT51U/Lγ-GT101U/L 0% 20% 40% 60% 80% 100% / 43
18 41.8% 34.2% 58.2% 65.8% 41.8% 34.2% 18 / 43
19 15.3%p % 31.2%10.5%7.4% 32.1%10.7%6.7% 1.9% 2.5% 2.6% 4.2% 5.5% 1.6% 6.2% 6.7% 1.5% 7.4% 1.4% 10.5% 0.9% 0.7% 15.3% 31.2% 19 / 43
20 20 / % 32.1% 10.7% 6.7% 5.7% 5.1% 4.7% 3.4% 1.8% 1.8% 1.6% 1.3% 1.3% 1.3% 0.7% 0.6%
21 3 40.1% 35.0% 59.9% 65.0% 40.1% 35.0% 21 / 43
22 17.1%p % 33.0%10.2%6.7% 31.7%10.6%6.4% 1.3% 1.7% 2.4% 2.6% 3.6% 4.4% 6.4% 6.7% 6.7% 1.2% 1.3% 10.2% 17.1% 0.9% 0.6% 33.0% 22 / 43
23 23 / % 31.7% 10.6% 6.4% 6.0% 5.4% 4.9% 3.6% 1.9% 1.8% 1.6% 1.4% 1.4% 1.3% 0.7% 0.6%
24 % 32.6% 57.6% 67.4% 42.4% 32.6% 24 / 43
25 17.2%p % 30.0%10.6%7.4% 33.1%10.5%6.5% 1.6% 1.5% 2.5% 1.8% 2.6% 3.7% 5.2% 6.3% 6.6% 7.4% 1.3% 10.6% 0.9% 0.7% 17.2% 30.0% 25 / 43
26 26 / % 33.1% 10.5% 6.5% 5.5% 5.1% 4.5% 3.5% 1.7% 1.7% 1.6% 1.3% 1.3% 1.2% 0.7% 0.6%
27 %1 31.0%3 49.4% 69.0% 50.6% 31.0% 27 / 43
28 %1 p %11.7%11.5% %9.2%6.2% 2.4% 1.2% 1.5% 1.5% 1.2% 2.6% 3.1% 11.5% 4.3% 4.6% 4.8% 23.0% 6.0% 9.1% 11.5% 11.7% 28 / 43
29 1.3% 3.7% 1.3% 4.2% 4.5% 5.1% 6.2% 1.1% 1.2% 1.1% 0.9% 0.5% 0.4% 23.6% 9.2% 35.8% 29 / 43
30 20 10kg 71.0% 15.7% 29.0% 71.0% 15.7% 84.3% 30 / 43
31 8.4p % 1.9% 1.4% 1.9% 2.5% 1.0% 2.8% 8.4% 3.4% 4.2% 4.8% 7.2% 8.2% 31.0% 10.9% 8.6% 31 / 43
32 32 / % 32.5% 10.4% 5.5% 5.4% 5.2% 3.5% 3.3% 1.5% 1.4% 1.1% 1.0% 1.0% 0.9% %
33 p % 2159, % % 229, % 1124, % 356, % 534, % 262, % 228, % 272, % 382,198 7 LDL AST(GOT) ALT(GPT)-GT(-GTP) 5, ,925 p / 43
34 52.5% 1086, % 983, % 18.7% 1072, , % 441, % 159, % % 682, % 69, % 65, % 331, % 152, % % % 313, % 202, % 75, % 111, % 42, % 68, / 43
35 3,395,199 2,850, , , , , , , , , , , , ,815 84, , ,479 58, , ,785 35, ,683 29,665 13, / 43
36 (%) (%) 2,163, ,231, ,712, ,138, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , / 43
37 (%) 1,156, , , , , , , , , , , , , , , , ,575, , , , , , , , , , , , , , , , / 43
38 160mmHg 100mmHg 140mmHg 90mmHg 130mmHg 85mmHg 130mmHg 85mmHg (%) (%) (%) (%) 136, , , ,273, , , , ,856, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , / 43
39 LDL180mg/dL 1,000mg/dL LDL140mg/dL 300mg/dL LDL120mg/dL HDL<40mg/dL 150mg/dL LDL120mg/dL HDL40mg/dL 150mg/dL (%) (%) (%) (%) 159, , ,015, ,303, , , , ,060, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , / 43
40 126mg/dL HbA1c mg/dL HbA1c mg/dL HbA1c mg/dL HbA1c5.6 (%) (%) (%) (%) 166, , , ,350, , , , ,911, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , / 43
41 AST51U/L ALT51U/L -GT101U/L AST31U/L ALT31U/L -GT51U/L AST<31U/L ALT<31U/L -GT<51U/L (%) (%) (%) 356, , ,346, , , ,872, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , / 43
42 1,124, , , , , , , ,198 (%) , , , , , , , ,371 (%) , ,839 75, ,773 69,363 65,974 42,437 68,827 (%) / 43
43 43 / 43
<4D F736F F D208C C9F8DB8926C82A982E782DD82BD89C193FC8ED282CC8C928D4E8FF391D482C98AD682B782E992B28DB895AA90CD2E646F6378>
28 6 IT 26 1 326 4,499 433 40-74 100cm 2 100cm 2 BMI25kg/m 2 85cm90cm 85cm90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL HbA1c
LDL HbA1c6. 5% AST51 ALT51 - GT LDL180 1, mmHg 85mmHg 150mg/dL HDL 40mg/dL 100mg/dL HbA1c 5.6% mmhg mg/dl mg/
30 7 IT 28 335 704 4 16 40-74 1 3 1100cm 2 100cm 2 BMI25kg/m 2 285cm 90cm 385cm 90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL
[] 1
![[] 1](/thumbs/42/22960844.jpg "[] 1")
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
函館市_絵で見てわかる
70 75 26 2 27 1 2 3 4 5 6 7 8 9 4 6 6 6 8 10 10 10 10 12 21 21 22 26 28 30 32 34 36 2 3 70 75 701 28 75 6575 7075 28 75 3 4 5 75 65 26 28 75 65 75 1 1 70 7075 2 2 2 1 260 90 210 18 9012 160 18 100 183
21 70.9 22 62.9 22 90 80 60 40 23 58 17 42 31 77.5 9 22.5 1 n 40 40 0 2 2 5.0 50 0 3 3 7.5 60 3 12 15 37.5 70 12 5 17 42.5 80 1 1 2 5.0 90 1 0 1 2.5 4
462015 Nagoya community school for health Think health scientifically : the life style and the health condition of seminar participants Hisae USAMI 21 36 67 1/3 21 21 21 1 23 6 68.2 91 43 70 42.56037.5
,995,972 6,992,875 1,158 4,383,372 4,380,511 2,612,600 2,612, ,433,188 3,330, ,880,573 2,779, , ,
p.2 p.3 25 p. 4p.5 1,158699 2,875 25 p. 6p. 15 484333 310 23-25 p.16 p. 27 31325 2,213,473 24 2,058,412 23 1,943,271 313 3 699 2,875 63.31% 36.69% 47.70% 18.22% p.4 p.5 13% 25.22% 20.74% 16.23% p.6 16.76%
180 140 22
21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3
<82D282A982C1746F95F18D908F57967B95B E696E6464>
1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9
6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61
A B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
001-029_”÷’X
54 2012 1 29 Kimori Daisuke Kamijo Takashi Takahashi Akira 1993 19951997 2001 10 1993 1999 1992 54 2012 1993 20 LDH BUNCRE UA CPK GOT CPK LDH UA CPK LDH UA CPK 1989 2001 2000 1989 1995 2003 2005 1989 54
無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
untitled
2 5 1 5 5.1 5.2 5.3 5.4 5.1 5.3 6 6.1 6.2 2 6.3 F 6.4 2 6.5 6.6 2 2 6.1 6.4 2 6.2 2 6.3 F 6.5 6.6 2 6.1 6.1 1 5 X N 2 /n Z X - / / n Z N 0 1 P -z /2 Z z /2 1- z P Z z = P X-z /2 / n X+ z /2 / n 100 % X-z
387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
次世代育成支援行動計画
15 7 10 300 9 17 21 5 21 22 5 1 2 3 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 16 39 40 11 2 3 P P 41 42 13 3 70.4 86.0 33.3 35.1 75.3 91.5 28.8 36.2 49.0 28.7 14.0 10.0
5.3mg () 1 2SD 2 1.5SD 17 15 2 4 4 3 ( ) 瘙 3 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘 4 24 p * p ** IGF-I (ng/ml) 77.12±60.19 238.97±143.60 161.85±113.30 [124.08, 199.63] (p
BMI BMI
() () 2 QOL () () QOL 11 6 14 20 13.9 20 BMI 12 70 40 11 6 14 20 13.9 20 BMI 12 70 40 57.1 100 ) 1 100 1 250 11 11 430 315 73.3 494 247 50.0 322 60 18.6 12 70 62 88.6 100 18 57.1 1 100 1 250 430 315 73.3
Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl
( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11
家庭系パソコンの回収再資源化にかかる論点
1 134 1212 134 2 1 137 1212 (1) 12 12,102 40.2 4,865 2-1 12 21,497 2-2 50.1 2-3 1 kg 2 12 2-1 13 12% 2-1 (2) 2-2 4 4 7 2-3 4 (3) 13.8 2-4 46 10 80 3 3 4 3 2-5, 2-6 13 9 2-7 18 2 2 8 5,000 30 25% 25 2 2
01-表紙から目次.PDF
56 100 1,205 45 11 30 48 56 56 10 56 1. 2 2. 2 3. 3 5 5 7 14 1 11 1. 11 (1) 11 (2) 11 (3) 11 (4) 12 (5) 12 2. 12 (1) 12 (2) 13 (3) 13 (4) 14 (5) 14 (6) 14 (7) 15 (8) 15 2 16 1. 16 (1) 16 (2) 17 (3) 17
01
01 1111 2102 1201 1101 2104 2106 2109 2107 1104 1112 1107 2114 2401 1108 1202 1203 2202 1103 2151 2158 2115 2116 2117 2101 1109 1105 1113 2404 02 No.1101 2,381 No.1103 2,667 No.1104 953 No.1108 2,858 No.1109
MNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2
2008 American Diabetes Association, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008 Jan; 31 Suppl 1: S61-S78.
広報かみやま
http://www.town.kamiyama.lg.jp 新 町 議 会 議 員 紹 介 27121520 10 21 28 1 6 1 28 441826 2 35 NGUYEN THI TRANG 6814 28 10 2 2 4 336 3 25 CONG HUI LOVE EVERLY AIXI 1 2 1020 5 5 TEL05702001780570200291 TEL05707835780570064738
16 41 17 22 12 10
1914 11 1897 99 16 41 17 22 12 10 11 10 18 11 2618 12 22 28 15 1912 13 191516 2,930 1914 5,100 43 1.25 11 14 25 34364511 7.54 191420 434849 72 191536 1739 17 1918 1915 60 1913 70 10 10 10 99.5 1898 19034.17.6
製品案内 価格表 2014/4/1
4 (17) 3 43 5/20370/ 231(504,150) 11 12 10 14-16 10 3 100 17 100kg 5-6 3 13 3 18 18 # # # # #$$ %&$ ' ()* +,-% ' #). +,-%'% / ' # # #$ %&&&'( %)* +'(#$ #$ %&&&'( ++,-). +'(#$ #$ /'( + /0)- +'(#$ %&&&'(
３．ごみの減量方法.PDF
- 7 - - 8 - - 9 - - 10 - - 11 - - 12 - ( 100 ( 100 - 13-123,550,846 111,195,762 92,663,135 ( 12 25 37 49.2 16 33 49 65.6 15 30 44 59.0 2.5kg) ( 5kg) ( 7.5kg) ( k ( 123,550,846 111,195,762 92,663,135 (
... 6 1) 2) No. 01 02 03 04 05 06 07 08 09 10 11 12 No. 1 2 2 3 3cm 4 
untitled
21 14 487 2,322 2 7 48 4 15 ( 27) 14 3(1867) 3 () 1 2 3 ( 901923 ) 5 (1536) 3 4 5 6 7 8 ( ) () () 9 10 21 11 12 13 14 16 17 18 20 1 19 20 21 22 23 21 22 24 25 26 27 28 22 5 29 30cm 7.5m 1865 3 1820 5
1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11 17 1938 1945 2010 14 221 1945 10 1946 11 1947 1048 1947 1949 24
15 4 16 1988 63 28 19314 29 3 15 4 16 19283 15294 16 1930 113132 3 15 4 16 33 13 35 12 3 15 4 16 1945 10 10 10 10 40 1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11
裁定審議会における裁定の概要 (平成23年度)
23 23 23 4 24 3 10 11 12 13 14 () 1 23 7 21 23 12 14 (19 ) 30 1.876% 60 8 24 19 78 27 1 (10) 37 (3) 2 22 9 21 23 5 9 21 12 1 22 2 27 89 10 11 6 A B 3 21 12 1 12 10 10 12 5 1 9 1 2 61 ( 21 10 1 11 30 )
<91E6825289F1938C966B95FA8ECB90FC88E397C38B5A8F708A778F7091E589EF8EC08D7388CF88F5837D836A83858341838B566572312E696E6464>
Microsoft Word - 入居のしおり.doc
1 1 2 2 2 3 2 4 3 5 3 6 3 7 3 8 4 1 7 2 7 3 7 4 8 5 9 6 9 7 10 8 10 9 11 10 11 11 11 12 12 13 13 1 14 2 17 3 18 4 19 5 20 6 22 (1) 24 (2) 24 (3) 24 (4) 24 (5) 24 (6) 25 (7) 25 (8) 25 (9) 25 1 29 (1) 29
和県監査H15港湾.PDF
...1...1...1...1...1...1...1...1...2...2...2...3...3...3...5...5...10...11...12...13...13...13...14...14...14...14...14...14...15...15...15...15...15 ...16...17 14...17...18...18...19...21...23 2...25...27...27...28...28...28
( )
( ) () () 3 cm cm cm cm cm cm 1000 1500 50 500 1000 1000 1500 1000 10 50 300 1000 2000 1000 1500 50 10 1000 2000 300 50 1000 2000 1000 1500 50 10 1000 2000 300 30 10 300 1000 2000 1000 1500 1000
2002 (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (6) (7) (8) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6) (7) (8) No 2,500 3 200 200 200 200 200 50 200 No, 3 1 2 00 No 2,500 200 7 2,000 7
-26-
-25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- cm -39- -40- 1 2 3 4 4 3 2 1 5 5-41- -42- -43- -44- -45- -46- -47- -48- -49- -50- cm -51- -52- -53- -54- -55- -56- -57- -58- -59- -60-
-1- 4 1 2 4-2- -- 2 2 cm 0 80cm 2 80cm 80cm 80cm 50cm 80cm 50cm 6 80cm 100 50 50 cm 10 6 4 50cm 4 4 50cm -4- -5- cm 50cm 4 4 4 50cm 50cm 4 80cm 50cm 80cm 50cm 6 cm -6- 20 250cm 1 2 1 4 0cm 60cm cm cm 1
untitled
() () () () () ( ) () ( ) () ( ) () 2 () () 2 () () ( ) () () () 2 () () 2 3 ( ) () ( ) 2 3 4 () () 2 3 4 () () ( )( ) ( ) 2 ( ) 3 () () 2 3 () () 2 3 () () () () () () () () (( ) ( ) (( ))( )( ) ) 2 3
河川砂防技術基準・基本計画編.PDF
4 1 1 1 1 1 2 1 2.1 1 2.2 2 2.3 2 2.4 2 3 2 4 3 2 4 1 4 1.1 4 1.2 4 2 4 2.1 4 2.2 4 2.3 5 2.4 5 2.5 5 2.5.1 5 2.5.2 5 2.6 5 2.6.1 5 2.6.2 5 2.6.3 5 2.6.4 5 2.6.5 6 2.7 6 2.7.1 6 2.7.2 6 2.7.3 6 2.7.4
4 100g
100g 10 20 30 40 50 60 70 80 4 5 7 9 12 15 19 24 60 100 10 80 100 20 10 5 20 195 20-1- 60 60 15 100 60 100 15 15 15 100 15 15 60 100 10 60 100 100 15 10 10 60 100 15 10 15 10 5-2- 80 80 24 100 80 100 24
180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3)
12 12 72 (1) (2) (3) 12 (1) (2) (3) (1) (2) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (1) (2) 180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 30 16 (1) 31 (2) 31 (3) (1) (2) (3) (4) 30
untitled
1....1 2....2 2.1...2 2.2...2 3....14 3.1...14 3.2...14 4....15 4.1...15 4.2...18 4.3...21 4.4...23 4.5...26 5....27 5.1...27 5.2...35 5.3...54 5.4...64 5.5...75 6....79 6.1...79 6.2...85 6.3...94 6.4...
113 120cm 1120cm 3 10cm 900 500+240 10 1 2 3 5 4 5 3 8 6 3 8 6 7 6 8 4 4 4 4 23 23 5 5 7
訪問入浴Ｑ＆Ａ PDFファイ ル httpwww.care-mirai.commiraihomehelpe_buth.html.docx
4 450kg500kg 185cm 95kg 100kg 185 ( ) Vision , 40 8/138/15 1/11/3 1 13,000 11,700 9,500 3,500 13,000 11,700 9,500 3,500 http://www.care-mirai.com 1 37 38 1 1,000PPM soda premium 1,100ppm http://www.care-mirai.com/mirai/carbonated.html
untitled
280 200 5 7,800 6 8,600 28 1 1 18 7 8 2 ( 31 ) 7 42 2 / / / / / / / / / / 1 3 (1) 4 5 3 1 1 1 A B C D 6 (1) -----) (2) -- ()) (3) ----(). ()() () ( )( )( )( ) ( ) ( )( )( )( ) () (). () ()() 7 () ( ) 1
PowerPoint プレゼンテーション
の使用例 DPP-4 阻害剤からへの切り替え 57 歳女性糖尿病罹病期間 5 年 主訴 : 体重増加 身長 :165 cm 体重 :70.3 kg B M I:25.8kg/m 2 HbA1c:6.5 % 家族歴 : 無し TG:141mg/dl LDL-C:122mg/dl HDL-C:48mg/dl 尿 Alb 8.3mg/g cre 合併症 : 脂質異常症 DM 治療 :DPP-4 阻害剤 合併症治療薬
B B 10 7 581 10 8 582 10 9 583 B B 10 11 585 10 12 586 B 10 10 584 B
10 1 575 10 12 586 B B 10 1 575 10 2 576 B B 10 4 578 10 5 579 10 3 577 B 10 6 580 B B B 10 7 581 10 8 582 10 9 583 B B 10 11 585 10 12 586 B 10 10 584 B 11 1 587 11 12 598 B B 11 1 587 11 2 588 11 3 589
（資料２）第７回資料その１（ヒアリング概要）
2 3 4 5 6 7 8 9 10 11 12 13 1 1 1 1 5 1 6 533 4 505 722 13 3325 475 1 2 3 13 10 31 1 1 1 (1) 1 (2) 2 (3) 3 (4) 4 5 5 6 7 8 8 8 9 11 11 12 13 14 15 16 19 (1) (2) (3) (1) (5 ) 1 (10 ) ( ) (2) 2 4 (3) 3 3,100
IT 180 181 1) 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 (a) (b) (c) (d) (e) (f) (a) (a) (b) 214 215 216 (a) (a) (a)
-------------------------- ----------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------------
<4D F736F F D DEC8BC A95BD90AC E A982BA81698AB A B B4790DF90AB8EBE8AB FC89408A4F816A82CC93AE8CFC82C98AD682B782E9838C837C815B D
27 29 2 IT 1,234 1,447 2,130 1,200 3,043 4 3 75 75 70-74 -10 J00 J101 J110 J111 J118 J300 J302-304 J301 26,475,118 155,290,311 1,234 14,472,130 75,784,748 12,003,043 79,505,563 1 1.00% 0.62% 1.31% 9 12
, , ,210 9, ,
2006 5 642 7 2,671 35 732 1,727 602 489 386 74 373 533 305 1,210 9,786 2004 1,024 43.7 16.4 2004 978.6 40.2 2003 1 2006 5 1997 1998 1999 774 3,492 11 2,603 35 843 5,118 1,686 476 358 2000 738 3,534 11
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
学習の手順
NAVI 2 MAP 3 m 17 13 19 12 17 24 1 20 18 23 18 12 1 12 17 11 14 16 19 22 m 12 16 A 16 20 B 20 24 24 28 C 20 AC 40 cm AD A 0.20 12 0.300 B 0.200 0.12 12 C D 40 1.000 20 2 2 0 20 30 cm 14 1 1 160 160 16
緑化計画作成の手引き 26年4月版
http://www.city.shibuya.tokyo.jp/env/en_eventact/midori_ryokka.html 10 11 12 13 14 15 16 17 18 19 P10 P10 1 P12 2635 Fax (1) 47 03-5388-3554 http://www2.kankyo.metro.tokyo.jp/sizen/sinseisyo/e2/tebiki.htm
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu
sick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
ニチベイ 高遮蔽ブラインド セレーノグランツ 25・35
Glanz 2015 61 3 6.5 3 35mm 3 300cm400cm 6.5 1cm 35mm 35mm 25mm 25 35 C059S C011S C472S C471S C474S C473S C476S C475S C410S C411S C211S C210S C012S C061S C209S C413S C063S C407S C051S C013S C054S C408S
untitled
Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb
標準的な健診・保健指導の在り方に関する検討会
第 3 章保健指導対象者の選定と階層化 (1) 保健指導対象者の選定と階層化の基準 1) 基本的考え方生活習慣病の予防を期待できる内臓脂肪症候群 ( メタボリックシンドローム ) の選定及び階層化や 生活習慣病の有病者 予備群を適切に減少させることができたかを的確に評価するために 保健指導対象者の選定及び階層化の標準的な数値基準が必要となる 2) 具体的な選定 階層化の基準 1 内臓脂肪型肥満を伴う場合の選定内臓脂肪蓄積の程度を判定するため
untitled
~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/
untitled
1 2 3 4 5 6 7 cm kg 8 9 10 11 12 13 14 15 T A S H A A M.. N.. A.. B.. I 16 17 18 C 19 20 holding 21 22 23 24 STEP1 STEP2 STEP3 STEP4 STEP5 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
untitled
1 2 3 4 5 6 7 48.4 7 1 2 1210 2.5 10 15 37.5 6 8 2.5 10 3 25 19 2.5 15 3 55 37.5 4.5 10 5 25 19 4.5 15 5 55 19 4.5 15 5 92 37.5 1 4 550 3 2500 3 3 3 50 10 15 15 19 19 37.5 5 8 15 b 10 15 19 37.5
2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na
2.7.4 2.7.4.1 2.7.4.1.1 11 ADH 1 ADH 1 4 7 129-A*-003 129-B*-001 129-E*-001P 129-G*-001 129-H*-002 129-H*-004 129-H*-005 132 242 4 129-B*-004 129-C*-005P 129-H*-003 129-H*-006 44 ADH ADH 129-C*-001P 16
07.報文_及川ら-二校目.indd
8 01 01 4 4 1 5 16 18 6 006 H 18 4 011 H 6 4 1 5 1 5 007 H 19 5 009 1 5 006 007 009 011 9 10 4 000 H 1 4 5 004 H 16 4 004 009 H 1 5 4 4 5 1 4 006 011 1 1 4m 5m 10m 007 1 7 009 009 1 5 10 1 000kg 10a 006
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
中高齢者の健康・いきいきライフスタイルづくり調査
1 -- -- 10 11 12 1998-2000 Exercise: A Guide from the National Institute on Aging 1 61-80 26 T PHA Streptoccocal enterotoxin ASEA (IL-2; Th1 ) IL-4Th2 IgE T T - Bcl-2 Fas T PHA SEA IL2 T PHA SEA IL2
untitled
Ref. No: KiG14B23-Kokushi22-R01 22 1/23 Ans Ans 1 75 64 74 8 75 75 Ans 9 75.1 2010 Ans Ans 1000 Ans 85cm 90cm 25 130mmHg 85mmHg 100mg/dl HbA1c 5.6 HDL 150mg/dl HDL-C 40mg/dl 1 3 Ans 1 (): 2 (): 3 (): 4
1 2420128 1 1 6 3 2 198808 189/1 1988081891 3 4 5 JISJIS X 0208 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 1... 1... 2... 3... 3... 8... 8... 8... 9 2... 9... 9... 10... 11... 13...
Microsoft Word - 血液検査.docx
血液検査 検査の内容 液を採取してさまざまなを調べます 検査前日の注意 糖尿病といわれるのがいやで 検査数 前から 事量を減らしたり 運動したりする人がいますが ヘモグロビン A1C 値を調べるとにわか対策もわかりますので 普段どおりの状態で受けましょう 中性脂肪 糖など空腹でないと正しく評価できない検査項目があります 受診する施設の注意に従ってください 検査でわかること 液検査からわかることは多く